A Randomized, Placebo-controlled, Subject and Investigator Blinded Study Investigating the Safety, Tolerability and Preliminary Efficacy of 8-week Treatment With Intra-articular LRX712 to Regenerate Articular Cartilage in Patients With Mild/Moderate Knee Osteoarthritis
Latest Information Update: 20 Feb 2025
At a glance
- Drugs LRX-712 (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
Most Recent Events
- 13 Feb 2025 Status changed from active, no longer recruiting to completed.
- 31 Dec 2024 Planned End Date changed from 27 Feb 2025 to 17 Jan 2025.
- 29 May 2024 Planned End Date changed from 18 Feb 2025 to 27 Feb 2025.